446 related articles for article (PubMed ID: 27557643)
1. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
2. Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.
Babar A; Babar M; Zubair H; Shahid A; Rafique S; Bano M; Waleed MS; Khan M; Inayat A; Safi D
J Oncol Pharm Pract; 2024 Apr; 30(3):535-546. PubMed ID: 38454813
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Jakubowiak AJ; Jasielec JK; Rosenbaum CA; Cole CE; Chari A; Mikhael J; Nam J; McIver A; Severson E; Stephens LA; Tinari K; Rosebeck S; Zimmerman TM; Hycner T; Turowski A; Karrison T; Zonder JA
Br J Haematol; 2019 Aug; 186(4):549-560. PubMed ID: 31124580
[TBL] [Abstract][Full Text] [Related]
4. Selinexor in multiple myeloma.
Martino EA; Vigna E; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Torricelli F; Neri A; Morabito F; Gentile M
Expert Opin Pharmacother; 2024 Mar; 25(4):421-434. PubMed ID: 38503547
[TBL] [Abstract][Full Text] [Related]
5. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.
Kwanten B; Deconick T; Walker C; Wang F; Landesman Y; Daelemans D
Biomed Pharmacother; 2023 Apr; 160():114305. PubMed ID: 36731340
[TBL] [Abstract][Full Text] [Related]
6. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Xiu L; Cakana A; Parekh T; San-Miguel JF
Cancer; 2016 Jul; 122(13):2050-6. PubMed ID: 27191689
[TBL] [Abstract][Full Text] [Related]
7. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Tremblay G; Daniele P; Breeze J; Li L; Shah J; Shacham S; Kauffman M; Engelhardt M; Chari A; Nooka A; Vogl D; Gavriatopoulou M; Dimopoulos MA; Richardson P; Biran N; Siegel D; Vlummens P; Doyen C; Facon T; Mohty M; Meuleman N; Levy M; Costa L; Hoffman JE; Delforge M; Kaminetzky D; Weisel K; Raab M; Dingli D; Tuchman S; Laurent F; Vij R; Schiller G; Moreau P; Richter J; Schreder M; Podar K; Parker T; Cornell RF; Lionel K; Choquet S; Sundar J
BMC Cancer; 2021 Sep; 21(1):993. PubMed ID: 34488662
[TBL] [Abstract][Full Text] [Related]
8. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract][Full Text] [Related]
10. A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.
Durand M; Cabaud Gibouin V; Duplomb L; Salmi L; Caillot M; Sola B; Camus V; Jardin F; Garrido C; Jego G
J Exp Clin Cancer Res; 2024 May; 43(1):148. PubMed ID: 38773631
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
[TBL] [Abstract][Full Text] [Related]
12. Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer.
He Y; Mei J; Hao H; Liu F; Yi Y; Hu C; Zou F; Lu X
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6931-6941. PubMed ID: 36840755
[TBL] [Abstract][Full Text] [Related]
13. Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.
Wang H; Yuan S; Zheng Q; Zhang S; Zhang Q; Ji S; Wang W; Cao Y; Guo Y; Yang X; Geng H; Yang F; Xi S; Jin G; Zhang J; Gao Q; Bernards R; Qin W; Wang C
Gastroenterology; 2024 Jun; 166(6):1130-1144.e8. PubMed ID: 38262581
[TBL] [Abstract][Full Text] [Related]
14. RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor.
Wang X; Xu J; Li Q; Zhang Y; Lin Z; Zhai X; Wang F; Huang J; Gao Q; Wen J; Li L; Feng Y; Luo H; Li Q; Liu X; Li J; Zhao F; Zhang L; Niu T; Sun C; Zheng Y
Cancer Lett; 2024 Jan; 580():216486. PubMed ID: 37984724
[TBL] [Abstract][Full Text] [Related]
15. Treatment of multiple myeloma with selinexor: a review.
Huang Q; Zhao R; Xu L; Hao X; Tao S
Ther Adv Hematol; 2024; 15():20406207231219442. PubMed ID: 38186637
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
[TBL] [Abstract][Full Text] [Related]
17. P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
Lin KH; Rutter JC; Xie A; Killarney ST; Vaganay C; Benaksas C; Ling F; Sodaro G; Meslin PA; Bassil CF; Fenouille N; Hoj J; Washart R; Ang HX; Cerda-Smith C; Chaintreuil P; Jacquel A; Auberger P; Forget A; Itzykson R; Lu M; Lin J; Pierobon M; Sheng Z; Li X; Chilkoti A; Owzar K; Rizzieri DA; Pardee TS; Benajiba L; Petricoin E; Puissant A; Wood KC
Nat Cancer; 2022 Jul; 3(7):837-851. PubMed ID: 35668193
[TBL] [Abstract][Full Text] [Related]
18. Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.
Revia S; Neumann F; Jabs J; Orio F; Sirrenberg C; Zimmermann A; Amendt C; Albers J
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791158
[TBL] [Abstract][Full Text] [Related]
19. Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.
Gu X; Sun C; Xu J; Lin Z; Zhang L; Zheng Y
Hematology; 2023 Dec; 28(1):2187972. PubMed ID: 36920065
[TBL] [Abstract][Full Text] [Related]
20. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
